CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
51.58
-0.59 (-1.13%)
At close: Dec 2, 2025, 4:00 PM EST
51.61
+0.03 (0.06%)
After-hours: Dec 2, 2025, 7:56 PM EST
CRISPR Therapeutics AG Revenue
CRISPR Therapeutics AG had revenue of $889.00K in the quarter ending September 30, 2025, with 47.67% growth. This brings the company's revenue in the last twelve months to $38.34M, down -81.10% year-over-year. In the year 2024, CRISPR Therapeutics AG had annual revenue of $37.31M, down -89.95%.
Revenue (ttm)
$38.34M
Revenue Growth
-81.10%
P/S Ratio
117.67
Revenue / Employee
$97,550
Employees
393
Market Cap
4.92B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 37.31M | -333.89M | -89.95% |
| Dec 31, 2023 | 371.21M | 370.01M | 30,885.48% |
| Dec 31, 2022 | 1.20M | -913.77M | -99.87% |
| Dec 31, 2021 | 914.96M | 914.24M | 127,154.94% |
| Dec 31, 2020 | 719.00K | -288.87M | -99.75% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CRSP News
- 2 days ago - Meet the Beaten-Down Biotech Stock Cathie Wood Loves That Wall Street Says May Soar 50% - The Motley Fool
- 3 days ago - The Best Stocks to Buy With $1,000 Right Now - The Motley Fool
- 11 days ago - 3 Mid-Cap Growth Stocks That Have Mammoth Long-Term Potential - The Motley Fool
- 13 days ago - Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. - The Motley Fool
- 15 days ago - 1 Underrated Stock That Could Soar by 58%, According to Wall Street - The Motley Fool
- 19 days ago - CRISPR Therapeutics Post Q3 Earnings: Testing Investor Patience, But Still A Buy - Seeking Alpha
- 20 days ago - ARK Sold Almost 400,000 Shares of CRISPR Therapeutics. Is Cathie Wood Worried? - The Motley Fool
- 22 days ago - CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results - GlobeNewsWire